New hope for stomach pain? itopride study launches
NCT ID NCT07165301
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study follows 200 people with functional dyspepsia, a common stomach disorder causing fullness and pain after meals. Participants will take itopride as part of their normal care. Researchers will track symptom changes over 16 weeks to see if the drug helps in real-world settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- itopride
- What this could lead to
- If it works, this could confirm that itopride helps ease symptoms of functional dyspepsia in Western patients, offering a new treatment option.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. Itopride's effectiveness in Western populations is still uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPIGASTRIC PAIN SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UZ Leuven
Leuven, 3000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Wheat sensitivity linked to fatty liver? a new study investigates
- Ancient herbal mix targets dual gut disorders in one shot
- Digestive health mystery: study seeks to uncover hidden burden of stomach pain in rural bangladesh
- New hope for chronic stomach pain: DA-9701 put to the test
- Could ginger and perilla replace acid pills for stomach trouble?
- Gut bacteria mystery: 200 patients to help uncover hidden cause of stomach pain